CD274 and neoplasm: The median OS among patients who had a tumor PD-L1 combined positive score of 10% or more was 8.0 months (95% CI: 5.0–12.3) in the pembrolizumab group, as compared with 5.2 months (95% CI: 4.0–7.4) in the chemotherapy group (P = 0.005).